Amarin Corp Plc (AMRN)

[HDGabor]

H-

Again, however, none of the asserted claims as construed requires an actual comparison to a second patient in a control group. (Supra ¶ 197.) At most, some asserted claims require a statistically significant reduction in Apo B levels, which is exactly what Kurabayashi reported for patients taking purified EPA. (Kurabayashi at 523, 525, Table 3.)

Good find. Regarding the statement:

Claims 8 of the ’677 patent

The method of claim 1, comprising administering to the subject about 4 g of the pharmaceutical composition daily for the period of at least about 12 weeks to effect a reduction in apolipoprotein B compared to placebo control.

Best,
G